XML 31 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On November 11, 2024, the Company entered into a research collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which, following expiration of the Hart-Scott-Rodino Act waiting period, the Company and Novartis will collaborate on the discovery, research and pre-clinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. Under the terms of the agreement, Novartis agreed to pay to the Company an initial upfront fee of $150.0 million following expiration of the Hart-Scott-Rodino Act waiting period, and the Company will be eligible to receive up to $2.272 billion in total milestones across the initial programs. Such milestones consist of up to $892.0 million in discovery and development milestones and up to $1.38 billion in commercial milestones. The Company is also entitled to a tiered percentage royalty ranging from mid single-digits to low double-digits on products commercialized by Novartis under the agreement, subject to certain specified reductions. The Company also entered into an expanded three-year software agreement with Novartis that substantially increases Novartis' access to the Company’s computational predictive modeling technology and enterprise informatics platform.